Vol. 5 No. 10 (2025)
Reimbursement Recommendations

Glofitamab (Columvi)

decorative image of the issue cover

Published October 20, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Columvi in combination with gemcitabine and oxaliplatin be reimbursed by public drug plans for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are not candidates for autologous stem cell transplant (ASCT), if certain conditions are met.
  • Columvi in combination with gemcitabine and oxaliplatin should only be covered to treat adult patients with r/r DLBCL NOS who are not candidates for ASCT and have received at least 1 prior line of therapy, or have received 2 or more lines of systemic therapy and are ineligible to receive or cannot receive CAR T-cell therapy, or have previously received CAR T-cell therapy.
  • Columvi in combination with gemcitabine and oxaliplatin should only be reimbursed if prescribed by clinicians experienced in the treatment of aggressive lymphomas and the side effects of treatment, and if the cost of Columvi is reduced.